{
  "id": 13211779,
  "title": "This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street",
  "url": "https://urgent.news/2026/10/09/this-stock-is-up-more-than-560-this-year-but-it-could-drop-by-38",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T20:00:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/09/this-stock-is-up-more-than-560-this-year-but-it-could-drop-by-36-according-to-wall-street/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Moderna's (NASDAQ:MRNA) stock has surged over 560% this year, outpacing the S&P 500's modest 14% gain. The biotech's strong clinical and regulatory progress, including the approval of its influenza vaccine mFLUSIVA for patients aged 50 and older, has contributed to this impressive performance. However, Wall Street analysts are expressing concerns about the stock's valuation, with an average price target of $121 suggesting a potential 38% drop from its current level.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street",
        "url": "https://urgent.news/2026/10/09/this-stock-is-up-more-than-560-this-year-but-it-could-drop-by-38-13212714",
        "published": "2026-10-09T20:20:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}